CY1122604T1 - Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης - Google Patents
Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασηςInfo
- Publication number
- CY1122604T1 CY1122604T1 CY20201100026T CY201100026T CY1122604T1 CY 1122604 T1 CY1122604 T1 CY 1122604T1 CY 20201100026 T CY20201100026 T CY 20201100026T CY 201100026 T CY201100026 T CY 201100026T CY 1122604 T1 CY1122604 T1 CY 1122604T1
- Authority
- CY
- Cyprus
- Prior art keywords
- mcg
- dose
- equivalent
- angiotasin
- hypotension
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται, π.χ., με μία μέθοδο η οποία περιλαμβάνει χορήγηση σε ένα υποκείμενο το οποίο έχει σοκ υψηλής παροχής και το οποίο υποβάλλεται σε αγωγή με μια κατεχολαμίνη σε μια δόση ισοδύναμη με τουλάχιστον περίπου 0,2 mcg/kg/min νορεπινεφρίνης μιας δόσης αγγειοτασίνης II η οποία είναι αποτελεσματική για αύξηση της πίεσης του αίματος του υποκειμένου σε μια μέση αρτηριακή πίεση (MAP) περίπου 65 mm Hg ή μεγαλύτερη, και η οποία είναι αποτελεσματική για μείωση της δόσης της κατεχολαμίνης η οποία απαιτείται για διατήρηση μιας MAP περίπου 65 mm Hg στην ισοδύναμη περίπου 0,05 -2,0 mcg/kg/min νορεπινεφρίνης ή μικρότερη, ή στην ισοδύναμη περίπου 0,05 mcg/kg/min νορεπινεφρίνης ή μικρότερη.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361917576P | 2013-12-18 | 2013-12-18 | |
US201461955706P | 2014-03-19 | 2014-03-19 | |
PCT/US2014/071186 WO2015095535A1 (en) | 2013-12-18 | 2014-12-18 | Angiotensin ii alone or in combination for the treatment of hypotension |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122604T1 true CY1122604T1 (el) | 2021-03-12 |
Family
ID=53367119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100026T CY1122604T1 (el) | 2013-12-18 | 2020-01-13 | Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης |
Country Status (23)
Country | Link |
---|---|
US (7) | US9220745B2 (el) |
EP (2) | EP2986308B1 (el) |
JP (3) | JP6824739B2 (el) |
KR (3) | KR20230051721A (el) |
CN (3) | CN112546197A (el) |
AU (2) | AU2014364528C1 (el) |
BR (1) | BR112016013961A2 (el) |
CA (1) | CA2933601A1 (el) |
CY (1) | CY1122604T1 (el) |
DK (1) | DK2986308T3 (el) |
EA (1) | EA037823B1 (el) |
ES (1) | ES2771749T3 (el) |
HR (1) | HRP20200009T1 (el) |
HU (1) | HUE047062T2 (el) |
IL (1) | IL246162B (el) |
LT (1) | LT2986308T (el) |
MX (2) | MX2016008108A (el) |
NZ (1) | NZ721089A (el) |
PL (1) | PL2986308T3 (el) |
PT (1) | PT2986308T (el) |
RS (1) | RS59804B1 (el) |
SI (1) | SI2986308T1 (el) |
WO (1) | WO2015095535A1 (el) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9572856B2 (en) | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
ES2771749T3 (es) | 2013-12-18 | 2020-07-07 | The George Washington Univ A Congressionally Chartered Not For Profit Corporation | Angiotensina II en combinación para el tratamiento de hipotensión |
SG11201610897VA (en) * | 2014-07-08 | 2017-01-27 | Jolla Pharma | Methods for treating hypotension |
WO2016153558A1 (en) | 2015-03-20 | 2016-09-29 | Atkinson Arthur J | Use of angiotensin ii (aii) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps |
KR20180108630A (ko) * | 2016-01-07 | 2018-10-04 | 라 졸라 파마슈티칼 컴파니 | 혈관수축제의 투여 방법 |
CA3010781A1 (en) | 2016-01-07 | 2017-07-13 | La Jolla Pharmaceutical Company | Methods for administering angiotensin ii |
US11583568B2 (en) | 2017-04-14 | 2023-02-21 | La Jolla Pharma, Llc | Methods for administering angiotensin II |
TW201927331A (zh) * | 2017-12-15 | 2019-07-16 | 美商拉荷亞製藥公司 | 血管收縮素組合物及與其相關之方法 |
WO2023244552A1 (en) * | 2022-06-15 | 2023-12-21 | Virginia Commonwealth University | Methods for fluid resuscitation of an organ donor |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU181008B (en) | 1980-01-18 | 1983-05-30 | Richter Gedeon Vegyeszet | Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position |
US5216025A (en) * | 1989-09-13 | 1993-06-01 | Board Of Regents, The University Of Texas System | Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients |
US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
WO2002098906A1 (en) | 2001-06-04 | 2002-12-12 | Human Genome Sciences, Inc. | Methods and compositions for modulating ace-2 activity |
US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
JP2007510643A (ja) | 2003-11-06 | 2007-04-26 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | 医薬化合物 |
NO20034952D0 (no) | 2003-11-06 | 2003-11-06 | Amersham Health As | Farmasöytiske forbindelser |
FR2880807B1 (fr) * | 2005-01-19 | 2007-04-13 | Aguettant Sa Lab | Composition pharmaceutique injectable |
EP1942985B1 (en) | 2005-09-29 | 2011-04-27 | Fibrogen, Inc. | Methods for reducing blood pressure |
AU2006332449B2 (en) * | 2005-12-30 | 2008-05-15 | Howard Florey Institute Of Experimental Physiology And Medicine | A method of treatment |
US20070293552A1 (en) | 2006-06-15 | 2007-12-20 | Gorczynski Richard J | Antihypertensive therapy method |
WO2008130217A1 (en) * | 2006-08-08 | 2008-10-30 | Applied Nanosystems B.V. | Cyclic angiotensin analogs |
BRPI0719319A2 (pt) | 2006-11-17 | 2014-02-04 | Da Volterra | Liberação colônica usando contas de zn/pectina com um revestimento de eudragit |
WO2009009907A1 (en) | 2007-07-18 | 2009-01-22 | The University Of British Columbia | Use of vasopressin-receptor agonists for the treatment of septic shock |
EP2161030A1 (en) * | 2008-09-09 | 2010-03-10 | Rijksuniversiteit te Groningen | Oxytocin formulations and uses thereof |
EP2350649A4 (en) | 2008-11-28 | 2012-11-14 | Abbott Lab | STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME |
US9572856B2 (en) * | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
FR2959414B1 (fr) * | 2010-04-30 | 2016-01-08 | Luc Quintin | Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire |
KR20130026504A (ko) | 2010-07-14 | 2013-03-13 | 큠버랜드 에멀징 테크놀로지스 아이앤씨 | 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법 |
EP3858437A1 (en) | 2013-04-26 | 2021-08-04 | La Jolla Pharma, LLC | Compositions and methods for treating renal failure |
ES2771749T3 (es) | 2013-12-18 | 2020-07-07 | The George Washington Univ A Congressionally Chartered Not For Profit Corporation | Angiotensina II en combinación para el tratamiento de hipotensión |
US20150286797A1 (en) | 2014-04-02 | 2015-10-08 | David R. Ratto | System and method for administering medication |
SG11201610897VA (en) | 2014-07-08 | 2017-01-27 | Jolla Pharma | Methods for treating hypotension |
KR20180108630A (ko) | 2016-01-07 | 2018-10-04 | 라 졸라 파마슈티칼 컴파니 | 혈관수축제의 투여 방법 |
CA3010781A1 (en) | 2016-01-07 | 2017-07-13 | La Jolla Pharmaceutical Company | Methods for administering angiotensin ii |
US11583568B2 (en) | 2017-04-14 | 2023-02-21 | La Jolla Pharma, Llc | Methods for administering angiotensin II |
TW201927331A (zh) | 2017-12-15 | 2019-07-16 | 美商拉荷亞製藥公司 | 血管收縮素組合物及與其相關之方法 |
-
2014
- 2014-12-18 ES ES14872684T patent/ES2771749T3/es active Active
- 2014-12-18 PT PT148726847T patent/PT2986308T/pt unknown
- 2014-12-18 WO PCT/US2014/071186 patent/WO2015095535A1/en active Application Filing
- 2014-12-18 JP JP2016539318A patent/JP6824739B2/ja active Active
- 2014-12-18 LT LTEP14872684.7T patent/LT2986308T/lt unknown
- 2014-12-18 DK DK14872684.7T patent/DK2986308T3/da active
- 2014-12-18 KR KR1020237012136A patent/KR20230051721A/ko not_active Application Discontinuation
- 2014-12-18 SI SI201431450T patent/SI2986308T1/sl unknown
- 2014-12-18 BR BR112016013961A patent/BR112016013961A2/pt not_active Application Discontinuation
- 2014-12-18 CA CA2933601A patent/CA2933601A1/en active Pending
- 2014-12-18 CN CN202011494632.XA patent/CN112546197A/zh active Pending
- 2014-12-18 CN CN201480075899.1A patent/CN106061493A/zh active Pending
- 2014-12-18 US US14/575,127 patent/US9220745B2/en active Active
- 2014-12-18 EA EA201691258A patent/EA037823B1/ru unknown
- 2014-12-18 AU AU2014364528A patent/AU2014364528C1/en active Active
- 2014-12-18 MX MX2016008108A patent/MX2016008108A/es unknown
- 2014-12-18 RS RS20200021A patent/RS59804B1/sr unknown
- 2014-12-18 EP EP14872684.7A patent/EP2986308B1/en active Active
- 2014-12-18 CN CN202010824424.5A patent/CN111920939A/zh active Pending
- 2014-12-18 EP EP19197866.7A patent/EP3607962A1/en active Pending
- 2014-12-18 KR KR1020167019427A patent/KR102399383B1/ko active IP Right Grant
- 2014-12-18 PL PL14872684T patent/PL2986308T3/pl unknown
- 2014-12-18 KR KR1020227004084A patent/KR20220028125A/ko active Application Filing
- 2014-12-18 HU HUE14872684A patent/HUE047062T2/hu unknown
- 2014-12-18 NZ NZ721089A patent/NZ721089A/en unknown
-
2015
- 2015-11-13 US US14/941,301 patent/US10028995B2/en active Active
-
2016
- 2016-06-09 IL IL246162A patent/IL246162B/en active IP Right Grant
- 2016-06-17 MX MX2020011190A patent/MX2020011190A/es unknown
-
2018
- 2018-03-01 US US15/909,617 patent/US10493124B2/en active Active
- 2018-09-19 US US16/135,608 patent/US10765722B2/en active Active
-
2019
- 2019-04-12 US US16/382,850 patent/US11096983B2/en active Active
- 2019-08-23 JP JP2019153144A patent/JP7175506B2/ja active Active
-
2020
- 2020-01-03 HR HRP20200009TT patent/HRP20200009T1/hr unknown
- 2020-01-13 CY CY20201100026T patent/CY1122604T1/el unknown
- 2020-11-26 AU AU2020277230A patent/AU2020277230A1/en active Pending
-
2021
- 2021-07-20 US US17/380,311 patent/US11559559B2/en active Active
-
2022
- 2022-07-14 JP JP2022113327A patent/JP2022137224A/ja active Pending
-
2023
- 2023-01-23 US US18/157,933 patent/US20230226141A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122604T1 (el) | Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης | |
CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
MX2020001732A (es) | Tratamiento de las afecciones del sistema nervioso central. | |
EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
CY1124596T1 (el) | Φαρμακευτικη συνθεση τραμαδολης για οφθαλμικη χρηση | |
EA201690212A8 (ru) | Способы лечения или профилактики офтальмологических патологических состояний | |
EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний | |
CY1124759T1 (el) | Μεθοδοι για τη θεραπεια της οξειας νεφρικης βλαβης | |
CY1120490T1 (el) | Φαρμακο για την προληψη και/ή την θεραπευτικη αντιμετωπιση της πολυκυστικης νοσου των νεφρων | |
EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
AR120055A1 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal | |
CY1120906T1 (el) | Συνθεσεις οξπρενολολης για τη θεραπεια του καρκινου | |
EA201591424A1 (ru) | Способы лечения дефицита железа растворимым пирофосфатом железа | |
EA201991688A1 (ru) | Фармацевтические комбинации для лечения рака | |
EA201892631A1 (ru) | Дигидротестостерон и производные и промоторы дигидротестостерона в лечении рака | |
EA201891968A1 (ru) | Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства | |
EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
CY1123243T1 (el) | Ενωση προερχομενη απο πυραζολινη και η χρηση τησσε ενα θεραπευτικο σχημα εβδομαδιαιας δοσολογησης εναντια στην φλεγμονη και τον πονο που προερχονται απο την εκφυλιστικη ασθενεια των αρθρωσεων στα θηλαστικα | |
EA201891008A2 (ru) | Лечение симптомов, связанных с андроген-депривационной терапией | |
EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ | |
MX2016003525A (es) | Agentes dirigidos contra una interaccion cis de molecula de orientacion repulsiva a (rgma) /neogenina o balsas lipidicas y uso de los mismos en metodos de tratamiento. | |
DOP2014000258A (es) | Tratamiento de la metástasis en el cerebro con una combinación de veliparib y una terapia con radiación en la totalidad del cerebro | |
CY1121404T1 (el) | Ενωσεις (ετερο)αρυλ-κυκλοπροπυλαμινης ως αναστολεις lsd1 |